UCSF COVID-19: Extended Immunophenotyping Studies
- Funded by National Institutes of Health (NIH)
- Total publications:2 publications
Grant number: 3U19AI077439-13S1
Grant search
Key facts
Disease
COVID-19Start & end year
20202022Known Financial Commitments (USD)
$506,680Funder
National Institutes of Health (NIH)Principal Investigator
DAVID J ERLEResearch Location
United States of AmericaLead Research Institution
UNIVERSITY OF CALIFORNIA-SAN FRANCISCOResearch Priority Alignment
N/A
Research Category
Pathogen: natural history, transmission and diagnostics
Research Subcategory
Immunity
Special Interest Tags
Innovation
Study Type
Clinical
Clinical Trial Details
Unspecified
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified
Abstract
We propose to rapidly apply key assays of patient samples derived from IMPACC studies tounderstand the critical features that characterize hospitalized patients with COVID-19, a pandemicdisease characterized by immune exacerbations of lung injury. These proposed studies are a naturaland focused extension of the work we are performing in the parent U19 award adapted to the urgentmedical need to better understand the pathogenesis of severe, life-threatening COVID-19 disease.We propose 5 site-specific studies that are highly complementary to assays being performed by theIMPACC national immunophenotyping cores here at UCSF and elsewhere. These include studiesthat focus on both airway cells and blood immune cells (including neutrophils) and utilize a set ofinnovative methods that allow for a detailed understanding of the nature and activation states ofspecific cell types within the airway and the blood. These studies promise to yield new insightsrelevant for understanding COVID-19 immunopathogenesis and predicting disease outcome andresponse to therapy, and could lead to novel therapeutic targets for this devastating disease.
Publicationslinked via Europe PMC
Last Updated:an hour ago
View all publications at Europe PMC